TY - JOUR
T1 - In vivo positron emission tomography imaging of decreased parasympathetic innervation in the gut of vagotomized patients
AU - Fedorova, Tatyana Dmitrievna
AU - Knudsen, Karoline
AU - Hartmann, Bolette
AU - Holst, Jens J.
AU - Mortensen, Frank Viborg
AU - Krogh, Klaus
AU - Borghammer, Per
PY - 2020
Y1 - 2020
N2 - Background Parasympathetic neuropathy is a key feature in many common disorders, including diabetes, neurological disorders, and cancers, but few objective methods exist for assessing damage to the parasympathetic nervous system, particularly in the gastrointestinal system. This study aimed to validate the use of C-11-donepezil positron emission tomography (PET) to assess parasympathetic integrity in a group of vagotomized patients.Methods Sixteen healthy controls and 12 patients, vagotomized due to esophagectomy, underwent C-11-donepezil PET, measurement of colonic transit time, quantification of plasma pancreatic polypeptide (PP), and assessment of subjective long-term symptoms.Key Results Vagotomized patients had significantly decreased PET signal in the small intestine and colon compared with healthy controls (5.7 [4.4-7.9] vs 7.4 [4.5-11.3], P = .01 and 1.4 [1.1-2.1] vs 1.6 [1.4-2.4], P <.01, respectively). Vagotomized patients also displayed a significantly increased colonic transit time (2.9 +/- 0.9 h vs 1.9 +/- 0.8 h), P <.01 and increased volumes of the small intestine and colon (715 ccm [544-1177] vs 443 ccm [307-613], P <.01 and 971 ccm [713-1389] vs 711 ccm [486-1394], P = .01, respectively). Patients and controls did not differ in PP ratio levels after sham feeding, but PP ratio at 10 minutes. after sham feeding and PET signal intensity in the small intestine was positively correlated (P = .03).Conclusions and Inferences We found significantly decreased C-11-donepezil signal in the intestine of vagotomized patients, supporting that C-11-donepezil PET is a valid measure of intestinal parasympathetic denervation.
AB - Background Parasympathetic neuropathy is a key feature in many common disorders, including diabetes, neurological disorders, and cancers, but few objective methods exist for assessing damage to the parasympathetic nervous system, particularly in the gastrointestinal system. This study aimed to validate the use of C-11-donepezil positron emission tomography (PET) to assess parasympathetic integrity in a group of vagotomized patients.Methods Sixteen healthy controls and 12 patients, vagotomized due to esophagectomy, underwent C-11-donepezil PET, measurement of colonic transit time, quantification of plasma pancreatic polypeptide (PP), and assessment of subjective long-term symptoms.Key Results Vagotomized patients had significantly decreased PET signal in the small intestine and colon compared with healthy controls (5.7 [4.4-7.9] vs 7.4 [4.5-11.3], P = .01 and 1.4 [1.1-2.1] vs 1.6 [1.4-2.4], P <.01, respectively). Vagotomized patients also displayed a significantly increased colonic transit time (2.9 +/- 0.9 h vs 1.9 +/- 0.8 h), P <.01 and increased volumes of the small intestine and colon (715 ccm [544-1177] vs 443 ccm [307-613], P <.01 and 971 ccm [713-1389] vs 711 ccm [486-1394], P = .01, respectively). Patients and controls did not differ in PP ratio levels after sham feeding, but PP ratio at 10 minutes. after sham feeding and PET signal intensity in the small intestine was positively correlated (P = .03).Conclusions and Inferences We found significantly decreased C-11-donepezil signal in the intestine of vagotomized patients, supporting that C-11-donepezil PET is a valid measure of intestinal parasympathetic denervation.
KW - acetylcholinesterase
KW - esophageal neoplasms
KW - parasympathetic nervous system
KW - positron emission tomography
KW - vagotomy
KW - VAGAL-SPARING ESOPHAGECTOMY
KW - QUALITY-OF-LIFE
KW - PANCREATIC-POLYPEPTIDE
KW - PARKINSONS-DISEASE
KW - ACETYLCHOLINESTERASE DENSITY
KW - PERIPHERAL ORGANS
KW - BIODISTRIBUTION
KW - DYSFUNCTION
KW - NEUROPATHY
KW - DOSIMETRY
U2 - 10.1111/nmo.13759
DO - 10.1111/nmo.13759
M3 - Journal article
C2 - 31715652
VL - 32
JO - Neurogastroenterology and Motility
JF - Neurogastroenterology and Motility
SN - 1350-1925
IS - 3
M1 - 13759
ER -